39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners acquired 39,241 Amylyx shares worth approximately $705,000 in the second quarter. Institutional investors collectively own 95.84% of AMLX, with several major funds increasing their positions.
• Amylyx shares rose 9.9% to $38.60, near the stock’s 12-month high of $39.07. The company reported a quarterly loss of $0.39 per share, missing analysts’ $0.36-per-share estimate.
• Analysts remain broadly bullish following positive Phase 3 avexitide results, with several firms raising price targets to between $42 and $55. However, regulatory review, an FDA filing, and approval remain ahead, creating potential volatility.

GSA Capital Partners LLP bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 39,241 shares of the company's stock, valued at approximately $705,000.

Other hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in shares of Amylyx Pharmaceuticals by 17.1% in the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company's stock worth $12,544,000 after buying an additional 131,944 shares during the last quarter. Bank of New York Mellon Corp raised its position in Amylyx Pharmaceuticals by 15.5% during the first quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company's stock valued at $3,490,000 after acquiring an additional 33,757 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Amylyx Pharmaceuticals by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company's stock valued at $70,123,000 after acquiring an additional 531,162 shares during the period. Stempoint Capital LP lifted its holdings in Amylyx Pharmaceuticals by 18.5% in the first quarter. Stempoint Capital LP now owns 669,685 shares of the company's stock valued at $9,309,000 after acquiring an additional 104,545 shares during the period. Finally, Siren L.L.C. acquired a new position in Amylyx Pharmaceuticals in the first quarter valued at approximately $17,097,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Trading Up 9.9%

NASDAQ AMLX opened at $38.60 on Thursday. The stock has a market capitalization of $4.30 billion, a price-to-earnings ratio of -26.99 and a beta of -0.21. The stock has a 50-day moving average of $19.38 and a 200 day moving average of $16.35. Amylyx Pharmaceuticals, Inc. has a twelve month low of $7.82 and a twelve month high of $39.07.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 success strengthens the product outlook. Avexitide met both the primary and secondary endpoints in the LUCIDITY trial, reducing hypoglycemic events by 55% in patients with PBH. The results provide Amylyx with a potentially important late-stage asset and support plans to submit an FDA application by the end of 2026. Reuters report on the avexitide trial
• Positive Sentiment: Analysts raised targets and ratings. Guggenheim lifted its target to $55 and assigned a “buy” rating; Robert W. Baird raised its target to $52 with an “outperform” rating; and H.C. Wainwright increased its target to $55 while maintaining a “buy” rating. Wolfe Research also upgraded the shares to “strong buy.” Benzinga analyst-rating updates
• Positive Sentiment: Investors are pricing in commercialization potential. Coverage characterized the trial as a major catalyst that could move avexitide closer to regulatory review and eventual commercialization, helping explain the unusually high trading activity and fresh stock high. Zacks analysis of Amylyx’s Phase 3 win
• Neutral Sentiment: Important milestones remain ahead. The results are topline data, so additional analysis, regulatory discussions, a formal FDA filing, and approval are still required. Commentary also cautioned that the sharp rally may have moved ahead of near-term fundamentals, increasing volatility and profit-taking risk. Invezz analysis of AMLX risks

Analysts Set New Price Targets

A number of brokerages have recently commented on AMLX. Mizuho raised their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday. HC Wainwright boosted their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday. Citigroup increased their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Finally, Robert W. Baird raised their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $36.25.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 10.90% of the stock is currently owned by insiders.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source